Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Haemonetics Corporation designs, manufactures, and markets automated blood processing systems. This report covers the unaudited financial results for the quarter ended June 28, 2003 (Fiscal 2004 Q1), compared to the quarter ended June 29, 2002.
Key Financial Metrics
| Metric | Q1 2004 (Jun 28, 2003) | Q1 2003 (Jun 29, 2002) |
|---|---|---|
| Net Revenues | $88.3 million | $81.9 million |
| Gross Profit | $39.6 million (44.8% margin) | $38.6 million (47.1% margin) |
| Operating Income | $8.2 million (9.3% margin) | $9.7 million (11.8% margin) |
| Net Income | $5.0 million | $6.8 million |
| Diluted EPS | $0.21 | $0.26 |
| Cash from Operations | $2.9 million | $1.3 million |
| Cash & Equivalents | $50.2 million | $42.0 million |
| Total Debt (Current + Long-term) | $70.1 million | N/A (Balance sheet not provided for prior year) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 7.7% ($6.3 million), driven by volume increases in disposables and miscellaneous services, as well as favorable foreign currency effects. International sales grew 11.2% to $56.7 million.
- Profitability Decline: Despite revenue growth, operating income decreased 15.5% and net income dropped 26.5%. This was primarily due to increased operating expenses (up 8.4%) driven by foreign currency translation and higher selling/marketing spend, which offset gross profit gains.
- Product Performance: Red Cell disposable sales surged 29.4% due to U.S. blood shortages driving automation adoption. Surgical and Blood Bank disposables grew 6.0% and 7.9% respectively. Plasma sales grew 3.2% but faced volume declines in Japan and the U.S.
- Cash Flow: Operating cash flow improved significantly to $2.9 million from $1.3 million, aided by lower inventory spending compared to the prior year.
Outlook, Risks, and Unusual Items
- Reorganization (Subsequent Event): On August 12, 2003, the company announced a reorganization into "Donor" and "Patient" divisions, resulting in a 4% workforce reduction (approx. 60 employees) and an estimated $2.7 million charge for severance and related costs.
- Customer Concentration Risk: The company lost revenue from Alpha Therapeutic Corporation due to industry consolidation. Alpha holds exclusive purchasing contracts expiring between 2005 and 2009; future revenue is uncertain pending the completion of Baxter's potential acquisition of Alpha.
- Foreign Exchange: Approximately 64% of sales are international. While the company hedges currency risk, fluctuations in the Euro and Japanese Yen significantly impact reported results. A 10% strengthening of the U.S. dollar could increase the fair value of forward contracts by $8.8 million.
- Inventory Provision: A $0.9 million provision was taken for excess and obsolete inventory due to the phase-out of an older device and revised demand estimates.
Investor Verification Checklist
- Verify the impact of the $2.7 million reorganization charge on Q2 2004 earnings.
- Monitor the status of the Baxter/Alpha Therapeutic acquisition to assess future Plasma revenue stability.
- Review foreign currency hedge effectiveness given the 64% international revenue exposure.
- Assess the sustainability of Red Cell sales growth driven by temporary blood shortages.
- Confirm the timeline for the phase-out of the older device generation impacting inventory provisions.